CVI Holdings’s Humacyte HUMA Stock Holding History

CVI Holdings’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500,000	Closed	-$5.8M	–	959
2021 Q3	$5.8M	Buy	+500,000	New	+$5.72M	0.36%	70

Other funds holding HUMA

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

DCP

Diameter Capital Partners New York $1.07B AUM 152.29% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

GIA

Gladstone Institutional Advisory Palm Beach Gardens, Florida $2.7B AUM 23.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CVI Holdings's HUMA Position: Q4 2021 in Review

CVI Holdings sold out of Humacyte (HUMA) in Q4 2021, closing a stake of 500,000 shares — an estimated $5.8M sold.

CVI Holdings first reported a position in HUMA in Q3 2021 and held it in 1 quarter. The position peaked at $5.8M in Q3 2021. 61 funds tracked by Wall St. Rank hold HUMA as of Q4 2021.

CVI Holdings reported no remaining Humacyte position as of Q4 2021 after selling out during the quarter.
CVI Holdings sold 500,000 Humacyte shares in Q4 2021, an estimated $5.8M.
CVI Holdings first reported a position in Humacyte in Q3 2021 and held it in 1 quarter.
CVI Holdings's Humacyte position peaked at $5.8M in Q3 2021.
61 funds tracked by Wall St. Rank held Humacyte as of Q4 2021.

Based on CVI Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.